ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The THINKER Trial: Quality of Life Results at 6- and 12-Month Follow-Up among Hepatitis C-Negative Patients Who Received Kidney Transplants from Deceased Donors with Hepatitis C Infection

V. Potluri, D. Goldberg, A. Peter, B. Emily, B. Roy, S. Deirdre, M. Levine, J. Trofe-Clark, M. Bleicher, S. Goral, A. Sicilia, S. Nazarian, R. Reddy, P. Porrett, P. Reese.

Univ of Pennsylvania, Philadelphia, PA.

Meeting: 2018 American Transplant Congress

Abstract number: 44

Keywords: Donors, Kidney transplantation, marginal, Outcome

Session Information

Session Name: Concurrent Session: Kidney Infectious - Viral Hepatitis

Session Type: Concurrent Session

Date: Sunday, June 3, 2018

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:18pm-3:30pm

Location: Room 4C-4

Background: Short-term (6-month) data from the first 10 subjects in the pilot THINKER-1 trial (NCT02743897; funder: Merck) suggested that kidneys from HCV-infected donors could be safely transplanted into HCV-negative patients. However, nothing is known about quality of life outcomes for these patients, who may have a different transplant experience due to concerns about stigma or the risks of infection or treatment. We now report 12-month quality of life data on the 10 THINKER-1 recipients as well as 6-month data on 10 recipients from an expanded cohort (THINKER-2).

Methods: Participants completed the RAND-36 questionnaire – a widely validated quality of life instrument – at enrollment and at regular intervals post-transplant. The Physical Component Summary (PCS) score and Mental Component Summary (MCS) score are normalized to population standards, with higher scores indicating better quality of life.

Results: Median age was 58 years (IQR 50 – 62), 70% were male and 35% were self-reported black race. Normalized mean PCS scores declined at 4 weeks and then increased steadily; the mean PCS improvement from pre-transplant to 12-months was 8.6. Normalized mean MCS scores also declined at 4 weeks, however, the MCS scores subsequently returned to baseline and remained stable at the end of 12 months. The Figure shows trajectories over time in individual quality of life domains as well as the PCS and MCS.

In conclusion, quality of life remains generally stable or improves after transplantation using HCV-infected kidneys for uninfected recipients. Research is ongoing to determine specific reasons for these trends in quality of life. These findings provide additional evidence that transplantation with HCV-infected kidneys, followed by treatment, provides benefit to patients with end-stage renal disease.

CITATION INFORMATION: Potluri V., Goldberg D., Peter A., Emily B., Roy B., Deirdre S., Levine M., Trofe-Clark J., Bleicher M., Goral S., Sicilia A., Nazarian S., Reddy R., Porrett P., Reese P. The THINKER Trial: Quality of Life Results at 6- and 12-Month Follow-Up among Hepatitis C-Negative Patients Who Received Kidney Transplants from Deceased Donors with Hepatitis C Infection Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Potluri V, Goldberg D, Peter A, Emily B, Roy B, Deirdre S, Levine M, Trofe-Clark J, Bleicher M, Goral S, Sicilia A, Nazarian S, Reddy R, Porrett P, Reese P. The THINKER Trial: Quality of Life Results at 6- and 12-Month Follow-Up among Hepatitis C-Negative Patients Who Received Kidney Transplants from Deceased Donors with Hepatitis C Infection [abstract]. https://atcmeetingabstracts.com/abstract/the-thinker-trial-quality-of-life-results-at-6-and-12-month-follow-up-among-hepatitis-c-negative-patients-who-received-kidney-transplants-from-deceased-donors-with-hepatitis-c-infection/. Accessed June 6, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences